Announcements Trials
Browse Landscape

Phase

Phase 2 64Phase 1 43Phase 3 36Phase 1/2 25Phase 2/3 3Phase NA 2Phase EARLY_PHASE1 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

NIH 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, Large B-Cell, Diffuse 2Myasthenia Gravis 1Lymphoma, B-Cell, Marginal Zone 1Autoimmune Diseases 1

Interventions

Cisplatin 17Magnetic Resonance Spectroscopy 16Specimen Handling 13pembrolizumab 10Carboplatin 10Gemcitabine 9Paclitaxel 8Radiotherapy 7Radiation 7Platinum 71,2-diaminocyclohexaneplatinum II citrate 7Pemetrexed 6Nivolumab 6Doxorubicin 6Surgical Procedures, Operative 5Radiotherapy, Intensity-Modulated 5Docetaxel 5Dexamethasone 5Biopsy 5atezolizumab 4Rituximab 4Immunoglobulin G 4Disulfides 4Bevacizumab 4Temozolomide 3Standard of Care 3Ramucirumab 3Drug Therapy 3Cyclophosphamide 3Cetuximab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2/3 × Cyclophosphamide × 30 days × Clear all
NCT06193889 2026-05-15

KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

Kyverna Therapeutics

Phase 2/3 Recruiting
66 enrolled

Autoimmune Diseases, Myasthenia Gravis

NCT03984448 2026-05-13

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
363 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04799275 2026-05-13

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
422 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡